ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Guidance for Public Comment at Advisory Committee Meetings

December 10, 2010

Funding Opportunity: DOD Offering 10.5 Million For Lung Cancer Research

May 30, 2014

USC $2.5 Million contract Tops Last Minute FY 75 Rush of Awards

July 18, 1975

Heavy Smokers And Drinkers Have Different Brain Chemistry

May 30, 2003

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

May 18, 2007

FDA Approves SNDA For Gardasil For Anal Cancer And Precancerous Lesions

January 28, 2011